Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Vaccine exemptions for religious or personal beliefs are rising across the U.S. - 2Flourishing as a Charitable Pioneer: Individual Encounters in Generosity
- 3Vote in favor of your Number one kind of juice
- 4Starship success, a private moon landing and more: The top 10 spaceflight stories of 2025
- 5AfD faction in western Germany ousts councilman for firebrand speech
- The most effective method to Really Adjust Hypothesis and Practice in Your Brain science Studies
- Virtual Domains d: A Survey of \Inundation and Ongoing interaction Mechanics\ Computer game
- In the stomach of a mummified wolf pup, scientists find DNA from a woolly rhinoceros
- Spain's Easter processions draw more tourists amid Iran war
- 6 Travel Services for Colorful Get-aways: Pick Your Fantasy Escape
- Venezuelans in Madrid celebrate Maduro's capture
- Poland Crypto Bill Clears Sejm Again, Defying President — Will “Restrictive” Rules Stick?
- Careful Living: Embracing the Current Second
- Figure out How to Amplify the Resale Worth of Your Kona SUV
